Building Scalable Cell Therapy Workflows: Media, Process, and Automation in Action
Are you ready to simplify your MSC workflow? Would you like a reliable, scale-up-ready solution to support your MSC therapy development?
The road from early discovery to commercial manufacturing is rarely linear. Cell and gene therapies fail to scale when early media and material selection do not survive tech transfer. Media formulation choices, raw material strategy and process design in early development have a direct impact on scale-up success, cost of goods, and regulatory readiness.
Explore how to design a right-first time workflow with integrated cell culture media, process liquids, development services and automation solutions can de-risk tech transfer and accelerate time-to-patient.
WHAT TO EXPECT Part 1: The panel brings industry experts together to highlight how smart early development choices can set the stage for smoother tech transfer, stronger clinical outcomes, and commercial success.
- Current challenges in MSC therapy development
- Reducing variability in raw material and donor selection
- Building GMP considerations into early development
- Transitioning from bottles to closed bag systems, moving to automation
- Preparing processes for commercial manufacturing
PART 2:
The panel answers audience questions with an interactive Q&A.
